Bavarian Nordic — August 2021
-
Jeg er stadig ikke overbevist om, at BN nødvendigvis har bedre data end Pfizer/Moderna (godkendte) og især Novavax (ikke godkendt). Sjovt nok nævnes der fx ikke noget med T-cellerespons, som typisk netop vil være bedre ved mRNA-vacciner vs. VLP/proteinbaserede vacciner.
-
Det er jo kun foreløbige data. De samlede data fremlægges først om et par mdr
-
og ? Det er altid mega risikabelt at gå ind i en aktie på forventninger, men det giver altså også kasse nogle gange. Selv går jeg ind trinvist, når jeg ser en mulighed. Det gjorde jeg med Genmab og mange andre. Her er det så ud ov er Bava
gså Expres2ion. Den første mindre position er efter 1,5 år 12 doblet og den større portion er 5 doblet på godt et halvt år. -
Bavarian: Selvom det skulle vise sig, at vaccinen "bare" har samme effekt og ubetydelige bivirkninger, så fremstilles den til 1/ af en Moderna m.fl og kan opbevares ved stuetempetaturer, så mon ikke de afrikanske og asiatiske regeringer er til at handle med? De kommer til at sælge alt det, de kan producere...
-
-
Bavarian: Topchef fortrøstningsfuld om finansiering https://www.proinvestor.com/investornyt/687978/bavarian-topchef-fortrostningsfuld-om-finansiering
-
-
-
Ali Salanti (Adaptvac) skriver på Linkedin:
Great news on our SARS-COV-2 vaccine presented as a novel virus like particle formulation. First human trial data show that the vaccine is very well tolerated. The clinical site reports that “In contrast to licensed SARS-CoV-2 vaccines, ABNCoV2’s safety profile is comparable to licensed protein-based vaccine such as hepatitis B vaccines and well tolerated even at doses beyond those that induce maximal immune-responses”. -
But most importantly the vaccine induces very high antibody responses (up to 12 fold compared to convalescent sera). Responses that are several fold higher than best in class mRNA vaccines ????. The potency of the vaccine platform is highlighted by the fact that even in the absence of adjuvants do we get high tittered responses, and even at the low vaccine doses.
-
We originally believed the precise positioning of the ACE2 binding part of the SARS-COV-2 receptor binding domain on the rigid surface of the virus like particle should results in a focused anti-RBD response with superior virus neutralization efficacy, and indeed our data generated together with Århus University show that we effectively neutralize the delta variant but more importantly we also very effectively (and importantly, better than
-
convalescence sera and mRNA vaccine induced sera) neutralize the escape variants represented in our study including the Beta variant. This vaccine(candidate) is also characterized by being rock stable even at ambient temperatures for longer time periods, and combining this with superior antibody responses we hope such a vaccine can not only be deployed in this part of the world as a booster vaccine, but also in parts of the world where the cold chain cannot be assured. Sadly, only 1% of people
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind